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Background: Heart failure (HF) is associated with oxidative stress, and oxidative modification of cardiac myosin binding protein C 
(cMyBP-C) has been associated with diastolic dysfunction in HF. In animals models of diastolic HF, full-length cMyBP-C, cMyBP-C 
fragments, and glutathionylated cMyBP-C are elevated. Therefore, we investigated whether plasma cMyBP-C could be a biomarker for HF.
methods:  Intact cMyBP-C, its fragments, and S-glutathionylated cMyBP-C were detected from plasma samples from animals or human 
patients with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) using immunoprecipitation and 
sandwich ELISA methods.
results:  Human plasma level of circulating total cMyBP-C from both of HFrEF (2.01 ± 0.61 fold, P<0.05, N=30) and HFpEF (4.02 ± 1.4 
fold, P<0.05, N=14) patients was elevated compared to healthy control group. The level of cMyBP-C fragments were increased both of 
HFpEF (2.64 ± 0.45-fold, P<0.05) and HFrEF (2.94 ± 0.49-fold, P<0.05). The level of S-glutathionylated cMyBP-C was also increased 
in HFpEF patients (2.31± 0.47-fold, P=0.015) were increased compared to healthy control group (N=12). The plasma level of proteolytic 
fragments cMyBP-C were also elevated in both group of HFpEF (1.41 ± 0.12-fold, P<0.05) and HFrEF (1.93 ± 0.19-fold, P<0.05). Increases 
in total circulating cMyBP-C level were 50% greater in HFpEF than HFrEF. In vitro experiments using isolated cardiomyocytes from HF 
animal showed that oxidative stress promoted release of cMyBP-C into the blood flow in the absence of necrosis or apoptosis.
conclusion:  Elevated plasma level of cardiac-specific cMyBP-C may be a useful biomarker of heart failure.
